AR076862A1 - Microorganismos no replicantes y su efecto de refuerzo inmunologico. composicion. metodo para aumentar efectividad de probioticos - Google Patents
Microorganismos no replicantes y su efecto de refuerzo inmunologico. composicion. metodo para aumentar efectividad de probioticosInfo
- Publication number
- AR076862A1 AR076862A1 ARP100101620A ARP100101620A AR076862A1 AR 076862 A1 AR076862 A1 AR 076862A1 AR P100101620 A ARP100101620 A AR P100101620A AR P100101620 A ARP100101620 A AR P100101620A AR 076862 A1 AR076862 A1 AR 076862A1
- Authority
- AR
- Argentina
- Prior art keywords
- use according
- composition
- probiotics
- bifidobacterium
- combinations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 239000006041 probiotic Substances 0.000 title abstract 5
- 235000018291 probiotics Nutrition 0.000 title abstract 5
- 230000000694 effects Effects 0.000 title 1
- 230000001900 immune effect Effects 0.000 title 1
- 244000005700 microbiome Species 0.000 title 1
- 230000002787 reinforcement Effects 0.000 title 1
- 235000013305 food Nutrition 0.000 abstract 4
- 241000186000 Bifidobacterium Species 0.000 abstract 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 abstract 2
- 241000186012 Bifidobacterium breve Species 0.000 abstract 2
- 241000186605 Lactobacillus paracasei Species 0.000 abstract 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 abstract 2
- 229940009289 bifidobacterium lactis Drugs 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 241000186660 Lactobacillus Species 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- 230000001010 compromised effect Effects 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000013373 food additive Nutrition 0.000 abstract 1
- 239000002778 food additive Substances 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 235000013350 formula milk Nutrition 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 230000007124 immune defense Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 229940124589 immunosuppressive drug Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000002417 nutraceutical Substances 0.000 abstract 1
- 235000021436 nutraceutical agent Nutrition 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 210000001539 phagocyte Anatomy 0.000 abstract 1
- 235000013406 prebiotics Nutrition 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000000529 probiotic effect Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
- Dairy Products (AREA)
Abstract
Reivindicacion 1: El uso de probioticos que se transforman en no replicantes mediante un tratamiento térmico de al menos alrededor de 70°C durante al menos alrededor de 3 minutos, caracterizado porque es para la preparacion de una composicion para tratar o prevenir trastornos relacionados con una defensa inmunologica comprometida. Reivindicacion 2: El uso de acuerdo con la reivindicacion 1, caracterizado porque los probioticos se seleccionan del grupo que consiste de los géneros lactobacilos, bifidobacterias o combinaciones de los mismos, tales como las especies Lactobacillus paracasei, Lactobacillus rhamnosus, Bifidobacterium Iongum, Bifidobacterium lactis, Bifidobacterium breve o combinaciones de los mismos, por ejemplo las cepas Lactobacillus paracasei NCC2461, Lactobacillus rhamnosus NCC4007, Bifidobacterium Iongum NCC3001, Bifidobacterium lactis NCC281 8, Bifidobacterium breve NCC2950 o combinaciones de los mismos. Reivindicacion 4: El uso de acuerdo con una de las reivindicaciones anteriores, caracterizado porque el trastorno es seleccionado del grupo que consiste de infecciones, en particular infecciones bacterianas, virales, fungicas y/o parasitarias; deficiencias de fagocitos; niveles de inmunodepresion bajos a severos, tales como los inducidos por estrés o fármacos inmunodepresores, quimioterapia o radioterapia; estados naturales de sistemas inmunes menos inmunocompetentes como los de los neonatos o ancianos; alergias; y combinaciones de los mismos. Reivindicacion 5: El uso de acuerdo con una de las reivindicaciones anteriores, caracterizado porque la composicion se selecciona del grupo que consiste de composiciones alimenticias, productos alimenticios incluyendo alimentos para mascotas, bebidas, formulas nutricionales, formulas para alimentacion, nutracéuticos, aditivos alimentarios, composiciones farmacéuticas, composiciones cosméticas, medicamentos. Reivindicacion 6: El uso de acuerdo con una de las reivindicaciones anteriores, caracterizado porque la composicion comprende además un agente para el alivio del dolor o la fiebre, un agente estabilizador, un agente saborizante, un agente colorante, un lubricante, un probiotico y/o un prebiotico. Reivindicacion 9: El uso de acuerdo con una de las reivindicaciones anteriores, caracterizado porque la composicion contiene alrededor de 0,005 mg -1000 mg de probioticos no replicantes por dosis diaria.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09159929A EP2251022A1 (en) | 2009-05-11 | 2009-05-11 | Non-replicating micro-organisms and their immune boosting effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076862A1 true AR076862A1 (es) | 2011-07-13 |
Family
ID=40848602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101620A AR076862A1 (es) | 2009-05-11 | 2010-05-11 | Microorganismos no replicantes y su efecto de refuerzo inmunologico. composicion. metodo para aumentar efectividad de probioticos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120107290A1 (es) |
| EP (2) | EP2251022A1 (es) |
| JP (1) | JP2012526749A (es) |
| CN (1) | CN102724987A (es) |
| AR (1) | AR076862A1 (es) |
| AU (1) | AU2010247467A1 (es) |
| BR (1) | BRPI1011024A2 (es) |
| CA (1) | CA2761442A1 (es) |
| CL (1) | CL2011002852A1 (es) |
| MX (1) | MX2011012069A (es) |
| RU (1) | RU2011150187A (es) |
| TW (1) | TW201103552A (es) |
| WO (1) | WO2010130660A1 (es) |
| ZA (1) | ZA201109087B (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1012849A2 (pt) | 2009-05-11 | 2018-06-19 | Nestec Sa | lactobacillus johnsonii la1 ncc533 (cncm i-1225) e distúrbios imunes |
| TWI406665B (zh) * | 2010-09-01 | 2013-09-01 | Genmont Biotech Inc | 益生菌株ｇｍ－０８０用於製備治療心臟發炎與心臟細胞凋亡之醫藥組合物及其用途 |
| EP2455094A1 (en) * | 2010-11-11 | 2012-05-23 | Nestec S.A. | Non-replicating probiotic micro-organisms protect children against gastrointestinal infections |
| EP2455093A1 (en) * | 2010-11-11 | 2012-05-23 | Nestec S.A. | Non-replicating probiotic bacteria and prevention or treatment of infections in children |
| BR112013020312B1 (pt) * | 2011-02-09 | 2021-03-23 | Synbiotics Ab | Composições simbióticas para restauração e reconstituição da microbiota intestinal |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| WO2014083166A1 (en) * | 2012-11-29 | 2014-06-05 | Nestec S.A. | Synbiotic composition and use thereof |
| US20150313952A1 (en) * | 2012-11-29 | 2015-11-05 | Nestec S.A. | Synbiotic composition and use thereof |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| KR101640744B1 (ko) | 2014-05-07 | 2016-07-19 | 일동제약주식회사 | 고분자 다당 바인더에 컨쥬게이트된 락토바실러스 람노서스 rht-3201, 및 이의 아토피 예방 및 치료 용도 |
| HUE037476T2 (hu) | 2014-12-23 | 2018-08-28 | 4D Pharma Res Ltd | Pirin polipeptid és immunmodulálás |
| PE20171138A1 (es) | 2014-12-23 | 2017-08-09 | 4D Pharma Res Ltd | Modulacion inmunitaria |
| EA038405B1 (ru) | 2015-06-15 | 2021-08-24 | 4Д Фарма Рисёрч Лимитед | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ШТАММЫ БАКТЕРИИ Bifidobacterium breve, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПАТОЛОГИЧЕСКОГО СОСТОЯНИЯ, ОПОСРЕДОВАННОГО IL-17 ИЛИ Th17 |
| TW202223083A (zh) | 2015-06-15 | 2022-06-16 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物之用途 |
| RS59308B1 (sr) | 2015-06-15 | 2019-10-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| CN108289919A (zh) * | 2015-10-19 | 2018-07-17 | 株式会社明治 | 面向婴儿的抗过敏剂 |
| SG11201803275UA (en) * | 2015-10-19 | 2018-05-30 | Meiji Co Ltd | Infection protective agent for infants |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| PT3209310T (pt) | 2015-11-20 | 2018-04-20 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| TW201733601A (zh) | 2016-03-04 | 2017-10-01 | ４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2017173241A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
| AU2017240068B2 (en) | 2016-03-31 | 2022-12-15 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
| TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| ES2657665B1 (es) * | 2016-09-05 | 2018-12-17 | Pedro Jose DE LA FUENTE BLASCO | Productos para la salud con probióticos inactivados y uso de dichos productos |
| JP2020500860A (ja) | 2016-11-23 | 2020-01-16 | ゴジョ・インダストリーズ・インコーポレイテッド | プロバイオティック／プレバイオティックな有効成分を含む消毒薬組成物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| MA48939B1 (fr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| JP6978514B2 (ja) | 2017-05-24 | 2021-12-08 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | 細菌株を含む組成物 |
| CN107114794A (zh) * | 2017-06-06 | 2017-09-01 | 上海真合生物技术有限公司 | 用于增强抗过敏能力的益生菌组合物 |
| TW201919670A (zh) | 2017-06-14 | 2019-06-01 | 英商4D製藥研究有限公司 | 包含細菌品系之組成物 |
| DK3600363T3 (da) | 2017-06-14 | 2021-01-25 | 4D Pharma Res Ltd | Sammensætninger omfattende bakteriestammer |
| CA3066557A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| JP2019208486A (ja) * | 2018-06-08 | 2019-12-12 | 株式会社ブロマ研究所 | 乳酸菌含有組成物及び免疫賦活用組成物 |
| US20210268041A1 (en) * | 2018-06-22 | 2021-09-02 | Synformulas Gmbh | Non-viable bifidobacterium bifidum bacteria and uses thereof |
| US11497197B2 (en) * | 2018-07-18 | 2022-11-15 | University Of Connecticut | Methods for enhancing poultry growth and performance |
| KR20230119213A (ko) * | 2020-12-17 | 2023-08-16 | 신발란스 에스알엘 | 프로바이오틱 조성물 및 스트레스-관련 병태의 예방및/또는 치료에서 이의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1110555A1 (fr) * | 1999-12-22 | 2001-06-27 | Societe Des Produits Nestle S.A. | Agent anti-adhesion de la flore pathogene de la peau |
| ES2378811T3 (es) * | 2000-01-18 | 2012-04-18 | Societe des Produits Nestlé S.A. | Composiciones de alimento para mascotas que permiten tratar a los animales domésticos contra especies de helicobacter |
| JP4510376B2 (ja) * | 2000-10-06 | 2010-07-21 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 皮膚の免疫系のバランスを保つためのプロバイオティック乳酸菌の使用 |
| US20050180962A1 (en) * | 2003-01-30 | 2005-08-18 | Eyal Raz | Inactivated probiotic bacteria and methods of use thereof |
| CA2557834C (en) * | 2004-03-04 | 2012-05-22 | E-L Management Corporation | Skin treatment method with lactobacillus extract |
| JP5371169B2 (ja) * | 2004-09-24 | 2013-12-18 | コンビ株式会社 | 薬剤耐性菌感染防除剤 |
| KR100578395B1 (ko) * | 2005-11-11 | 2006-05-10 | 주식회사 바이오리더스 | 면역기능이 강화된 사균화 유산균 제제 및 그 제조방법 |
| RU2445362C2 (ru) * | 2006-02-15 | 2012-03-20 | Нестек С.А. | Применение bifidobacterium longum в производстве лекарственного средства или терапевтической питательной композиции для лечения воспалительного заболевания кишечника у млекопитающего и для ослабления воспаления кишечника, связанного с пищевыми аллергенами, у млекопитающего |
| MX2009008875A (es) * | 2007-02-28 | 2009-08-28 | Mead Johnson Nutrition Co | Producto que contiene probiotico inactivado para niños o infantes. |
| JP2008245569A (ja) * | 2007-03-30 | 2008-10-16 | Kirin Holdings Co Ltd | 高抗アレルギー活性を有する乳酸菌組成物及び該乳酸菌の製造方法 |
| ES2578261T3 (es) * | 2007-05-18 | 2016-07-22 | Nestec S.A. | Lactobacillus johnsonii para prevenir infecciones postoperatorias |
| WO2008153377A1 (en) * | 2007-06-15 | 2008-12-18 | N.V. Nutricia | Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide |
| EP2022502A1 (en) * | 2007-08-10 | 2009-02-11 | Nestec S.A. | Lactobacillus rhamnosus and weight control |
-
2009
- 2009-05-11 EP EP09159929A patent/EP2251022A1/en not_active Withdrawn
-
2010
- 2010-05-07 CA CA2761442A patent/CA2761442A1/en not_active Abandoned
- 2010-05-07 US US13/319,963 patent/US20120107290A1/en not_active Abandoned
- 2010-05-07 WO PCT/EP2010/056287 patent/WO2010130660A1/en not_active Ceased
- 2010-05-07 CN CN2010800311763A patent/CN102724987A/zh active Pending
- 2010-05-07 JP JP2012510234A patent/JP2012526749A/ja active Pending
- 2010-05-07 MX MX2011012069A patent/MX2011012069A/es not_active Application Discontinuation
- 2010-05-07 RU RU2011150187/02A patent/RU2011150187A/ru not_active Application Discontinuation
- 2010-05-07 BR BRPI1011024A patent/BRPI1011024A2/pt not_active IP Right Cessation
- 2010-05-07 EP EP10721416A patent/EP2429547A1/en not_active Withdrawn
- 2010-05-07 AU AU2010247467A patent/AU2010247467A1/en not_active Abandoned
- 2010-05-11 TW TW099115200A patent/TW201103552A/zh unknown
- 2010-05-11 AR ARP100101620A patent/AR076862A1/es not_active Application Discontinuation
-
2011
- 2011-11-11 CL CL2011002852A patent/CL2011002852A1/es unknown
- 2011-12-09 ZA ZA2011/09087A patent/ZA201109087B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2011002852A1 (es) | 2012-07-20 |
| AU2010247467A1 (en) | 2011-12-08 |
| MX2011012069A (es) | 2011-12-06 |
| RU2011150187A (ru) | 2013-06-20 |
| CA2761442A1 (en) | 2010-11-18 |
| TW201103552A (en) | 2011-02-01 |
| EP2429547A1 (en) | 2012-03-21 |
| JP2012526749A (ja) | 2012-11-01 |
| US20120107290A1 (en) | 2012-05-03 |
| CN102724987A (zh) | 2012-10-10 |
| EP2251022A1 (en) | 2010-11-17 |
| BRPI1011024A2 (pt) | 2019-09-24 |
| WO2010130660A1 (en) | 2010-11-18 |
| ZA201109087B (en) | 2013-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076862A1 (es) | Microorganismos no replicantes y su efecto de refuerzo inmunologico. composicion. metodo para aumentar efectividad de probioticos | |
| Heo et al. | Effects of dietary probiotic, Lactococcus lactis subsp. lactis I2, supplementation on the growth and immune response of olive flounder (Paralichthys olivaceus) | |
| CN102858354B (zh) | 包含用于婴儿和幼儿的益生菌的婴儿和幼儿喂养配方 | |
| Chatterjee et al. | Probiotics in periodontal health and disease | |
| JP6235138B2 (ja) | プレバイオティクス効果を有する組成物 | |
| MX2019011058A (es) | Moleculas probioticas para reducir virulencia patogena. | |
| PH12019501025A1 (en) | Natural compositions providing dietary management of colic | |
| RU2018139655A (ru) | Бифидобактерии для увеличения безжировой массы тела | |
| Onyenweaku et al. | Research Article Health Benefits of Probiotics | |
| RU2017122615A (ru) | Применение пробиотиков для усиления мужской фертильности | |
| SG188915A1 (en) | Sialic acid to support the immune system in the elderly | |
| Mikawlrawng et al. | Drug interactions, safety and efficacy of probiotics | |
| Figueiredo et al. | Probiotics in human health | |
| Yasmin et al. | Feed Additives as Antiviral Agents | |
| Agarwal | Probiotics--the health friendly gut bacteria. | |
| WO2021151956A1 (en) | Composition for treating intestinal or pulmonary diseases | |
| AU2016100500A4 (en) | Probiotic compositions for rehydration | |
| Kaur et al. | Probiotics–A new way to maintain oral health | |
| Bhunia | Bioengineered probiotics–A solution to broaden probiotics efficacy | |
| WO2018039090A1 (en) | Methods of use & compositions of ibd, ibs, & antineoplastic microbial therapeutics | |
| Chavda et al. | A Glance to the Patent World of Probiotics 15 | |
| Singh et al. | Probiotics in Pediatric and Neonate Healthcare | |
| Abdallah et al. | Antibacterial effects of probiotics isolated from milk products against some common bacterial pathogens | |
| PH12012000351A1 (en) | Whitening supplement with probiotics | |
| Vazquez et al. | Effects of several combinations of probiotics and prebiotics on the specific systemic immune response in an influenza vaccination mouse model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |